Dolby Stock Down 18%, Yet This $8 Million Bet Signals Turnaround Potential

This audio and imaging technology provider licenses Dolby Atmos and Vision to global entertainment and device markets.On February 13, 2026, Neo Ivy Capital Management disclosed a new position in Dolby Laboratories (DLB 0.83%), acquiring 117,964 shares in a trade estimated at $7.58 million.What happenedNeo Ivy Capital Management reported in a February 13, 2026, SEC filing that it established a new stake in Dolby Laboratories, acquiring 117,964 shares. The estimated transaction value was $7.58 million. What else to knowThis new position in DLB represents 1.2% of Neo Ivy’s reportable U.S. equity AUM after the fourth quarter filing.Top holdings after the filing:NYSE: F: $7.61 million (1.2% of AUM)NYSE: DLB: $7.58 million (1.2% of AUM)NYSE: WELL: $7.56 million (1.2% of AUM)NASDAQ: ROIV: $7.41 million (1.2% of AUM)NASDAQ: NVDA: $7.35 million (1.2% of AUM)As of February 12, 2026, shares of DLB were priced at $66.57, down 18.2% over the past year and underperforming the S&P 500 by 31.08 percentage points.Company overviewMetricValuePrice (as of market close 2026-02-12)$66.57Market Capitalization$6.37 billionRevenue (TTM)$1.34 billionNet Income (TTM)$276.72 millionCompany snapshotDolby Laboratories develops and licenses advanced audio and imaging technologies, including Dolby Atmos, Dolby Vision, and a suite of digital codecs for cinema, broadcast, streaming, and consumer electronics.The company generates revenue primarily through technology licensing agreements and sales of specialized hardware for entertainment and communications markets.It serves film studios, content creators, post-production facilities, cinema operators, broadcasters, and device manufacturers worldwide.Dolby Laboratories is a leading provider of audio and imaging innovations, leveraging its proprietary technologies to enhance entertainment experiences across multiple platforms. The company combines a robust licensing model with hardware solutions, enabling global reach and recurring revenue streams. Its established presence in both professional and consumer markets supports sustained growth and a defensible competitive position.What this transaction means for investorsDurable licensing franchises rarely trade at discounts for long. That tension makes this new stake in Dolby worth watching.Shares are down 18.2% over the past year, but the fundamentals tell a steadier story. In the first quarter of fiscal 2026, revenue totaled $347 million, down from $357 million one year prior but with $319.8 million coming from high-margin licensing streams. Meanwhile, gross profit reached $303.5 million, and the company generated $53.3 million in GAAP net income. And even more telling, Dolby repurchased roughly 1 million shares for about $70 million and still ended the quarter with $207 million remaining under its buyback authorization.That matters because this is not a capital-intensive turnaround story. It is a licensing machine with roughly 90% gross margins and a balance sheet showing over $640 million in cash and equivalents. Compared with other holdings clustered around cyclical industrial and commodity names, this adds a royalty-driven, asset-light counterweight.About the AuthorJonathan Ponciano is a contributing stock market analyst at The Motley Fool. He has nearly a decade of experience as a financial journalist, most recently as an editor and senior reporter at Forbes focused on markets, technology, and entrepreneurship. Jonathan has also written for Investopedia and the Los Angeles Business Journal. He holds a dual B.A. in Business Journalism and Economics from the University of North Carolina at Chapel Hill and an M.B.A. from Columbia Business School. A North Carolina native now based in New York City, Jonathan has also lived in Mexico City and Los Angeles.CMFjonponcStocks MentionedDolby LaboratoriesNYSE: DLB$66.02 (0.83%) $0.55*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.